Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan

Aliment Pharmacol Ther. 2017 Apr;45(7):1009-1010. doi: 10.1111/apt.13959.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Anti-Bacterial Agents
  • Cytochrome P-450 CYP3A*
  • Drug Therapy, Combination
  • Genotype
  • Helicobacter Infections
  • Helicobacter pylori*
  • Humans
  • Japan

Substances

  • Anti-Bacterial Agents
  • Cytochrome P-450 CYP3A